David Peleg, MD

• Department of Obstetrics and Gynecology
• Abington Memorial Hospital
• Abington, Pennsylvania

The effect of theophylline and enprofylline on allergen-induced bronchoconstriction muscle relaxant used in dentistry nimodipine 30 mg order with mastercard. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics spasms below sternum buy nimodipine 30 mg online. Modulation by theophylline and enprofylline of the excitatory non-cholinergic transmission in guinea-pig bronchi muscle relaxant cream cheap 30 mg nimodipine fast delivery. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma muscle relaxant otc usa purchase nimodipine 30 mg without a prescription. Effect of slow-release theophylline on nasal antigen challenge in subjects with allergic rhinitis spasms lower stomach nimodipine 30 mg purchase without a prescription. Twenty-four hour lung function in adult patients with asthma: chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Polymorphonuclear leukocyte inhibition by therapeutic concentrations of theophylline is mediated by cyclic-3,5-adenosine monophosphate. Immunomodulation by theophylline in asthma: demonstration by withdrawal of therapy. Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxophylline and tiotropium with budesonide: a randomized controlled study. Assessment of various second line medications in addition to inhaled corticosteroids in asthma patients: a randomized controlled trial. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Comparison of patients compliance with prescribed oral and inhaled asthma medications. Effects of theophylline on diaphragmatic strength and fatigue in patients with chronic obstructive pulmonary disease. Effects of fatigue, fiber length, and aminophylline on human diaphragm contractility. In vivo effects of theophylline on diaphragm, bicep, and quadricep strength and fatigability. Dyspnea and diaphragmatic fatigue in patients with chronic obstructive pulmonary disease. Effects of aminophylline on respiratory drive and neuromuscular coupling in normal man and in patients with chronic airflow obstruction. Theophylline improves gas exchange during rest, exercise, and sleep in severe chronic obstructive pulmonary disease. Hyperinflation, trapped gas and theophylline in chronic obstructive pulmonary disease. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. Adenosine A2b receptors evoke interleukin-8 secretion in human mast cells: an enprofylline-sensitive mechanism with implications for asthma. Isolated bronchi from asthmatics are hyperresponsive to adenosine, which apparently acts indirectly by liberation of leukotrienes and histamine. Pharmacological characterization of adenosine receptors on isolated human bronchi. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Acute anti-inflammatory effect of the novel phosphodiesterase 4 inhibitor roflumilast on allergen challenge in asthmatics after a single dose. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Roflumilast ­ an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomized controlled trial. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with long-acting bronchodilators: two randomised clinical trials. Randomized double blind controlled trial of roflumilast on acute exacerbations of chronic obstructive pulmonary disease. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Central role for G protein­ coupled phosphoinositide 3-kinase gamma in inflammation. Direct effects of caffeine and theophylline on p110 and other phosphoinositide 3-kinases. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomized dose-ranging study. Anti-inflammatory effects of the phosphodiesterase-4 inhibitor cilomast (Ariflo) in chronic obstructive pulmonary disease. Pharmacology, clinical efficacy, and tolerability of phosphodiesterase-4 inhibitors: impact of human pharmacokinetics. Effects of roflumilast, a phosphodiesterase 4 inhibitor, on body composition in chronic obstructive pulmonary disease. Roflumilast increases bacterial load and dissemination in a model of Pseudomonas aeruginosa airway infection. Inhibition of phosphodiesterase-4 during pneumococcal pneumonia reduces inflammation and lung injury in mice. The effect of selective and non selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways. Effect of the selective phosphodiesterase inhibitor on the early and late asthmatic response to inhaled allergen. Inhibitory effect of milrinone on cytokine production after cardiopulmonary bypass. Enoximone in contrast to dobutamine improves hepatosplanchnic function in fluid-optimized septic shock patients. Phosphodiesterase isoenzymes modulating inherent tone in human airways: identification and characterization. Disodium cromoglycate: activity in three in vitro models of the immediate hypersensitivity reaction in lung. Inhibition profiles of sodium cromoglycate and nedocromil sodium on mediator release from mast cells of human skin, lung, tonsil, adenoid and intestine. Effects of sodium cromoglycate on cytokine production following antigen stimulation of a passively sensitized human lung model. Sodium cromoglycate attenuates pulmonary inflammation without influencing bronchial responsiveness in healthy subjects exposed to organic dust. Pharmacological stabilization of mast cells abrogates late thrombotic events induced by diesel exhaust particles in hamsters. Ozone-induced mediator release from human bronchial epithelial cells in vitro and the influence of nedocromil sodium. Comparison of nedocromil sodium at two dosage frequencies with placebo in the management of chronic asthma. A controlled study of cromolyn sodium sponsored by the Drug Committee of the American Academy of Allergy. A multicenter evaluation of the clinical benefits of cromolyn sodium aerosol by metered-dose inhaler in the treatment of asthma. A comparative study of the clinical efficacy of nedocromil sodium and placebo: how does cromolyn sodium compare as an active control treatment The clinical efficacy of inhaled nedocromil sodium (Tilade) in the treatment of asthma. Ocular sodium cromoglycate: an overview of its therapeutic efficacy in allergic eye disease. Topical use of sodium cromoglicate (cromolyn sodium) to treat atopic dermatitis and other skin allergies. Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. Disodium cromoglycate inhibits SµS deletional switch recombination and IgE synthesis in human B cells. G-protein-coupled receptor 35 is a target of the asthma drugs cromolyn disodium and nedocromil sodium. Anti-allergic chromones inhibit histamine and eicosanoid release from activated human and murine mast cells by releasing Annexin A1. Cromoglycate drugs suppress eicosanid generation in U937 cells by promoting the release of Anx-A1. Novel role for mast cells in omental tissue remodeling and cell recruitment in experimental peritoneal dialysis. The pharmacokinetics of sodium cromoglycate in man after intravenous and inhalation administration. The efficacy of slow versus faster inhalation of cromolyn sodium in protecting against allergen challenge in patients with asthma. The most commonly used agent to evaluate this response, methacholine, produces bronchoconstriction by activating cholinergic receptors. For decades, anticholinergic agents were known to reduce acute bronchospasm in patients with asthma, and the anticholinergic agent tiotropium now has been approved as an add-on therapy for patients with moderate-to-severe asthma. Anticholinergic agents also have a defined role for treatment in some subsets of patients with rhinitis. Neurotransmission through parasympathetic ganglia is principally mediated by nicotinic receptors on postganglionic nerves that produce a fast excitatory postsynaptic potential. This fast potential can be positively and negatively modulated by postganglionic muscarinic receptors, and muscarinic receptors on other lung tissues can have other important effects. Muscarinic receptors, through altered expression and function, are thought to play a greater role than nicotinic receptors in the pathogenesis of obstructive lung disease, which provides the underlying pharmacologic rationale for using antimuscarinic receptor agents in treatment. Muscarinic receptors are concentrated in smooth muscle and are proximate to submucosal glands of the airways. They have the highest density in the proximal airways and hilum, which corresponds to where there is greatest parasympathetic innervation of the lungs. Whether these observations suggest a shift in the pathogenic mechanisms responsible for the clinical condition we describe as asthma is not clear. Muscarinic Receptor Subtypes in the Lung Five muscarinic receptor subtypes (M1 through M5), all of which are inhibited by atropine, have been identified and reviewed by Fryer and Jacoby. The M1, M3, and M5 receptors have a stimulatory cholinergic effect on target tissue and cells, whereas M2 receptors can be inhibitory or stimulatory, depending on their location, and M4 receptors are inhibitory. M1 receptors are principally postganglionic, where their stimulation promotes ganglionic transmission primarily mediated by nicotinic receptors. M1 receptors are also present on smooth muscle, where their stimulation can augment cholinergic reflex bronchoconstriction, but they are thought to have a less important role in bronchoconstriction than other subtypes of muscarinic receptors. M1 receptors on epithelial cells and submucosal glands also stimulate electrolyte and water secretion that contribute with mucin (the glycoprotein constituent of mucus released from several cellular sources in response to M3 stimulation) to produce mucus. At parasympathetic ganglia, prejunctional M2 receptors provide negative presynaptic feedback to inhibit acetylcholine release to modulate cholinergic responses. Blocking prejunctional M2 receptors with pharmacologic agents can increase acetylcholine release, with the potential to increase cholinergically mediated bronchoconstriction. M2 receptors are the most highly expressed muscarinic receptors on airway smooth muscle, but they are less clinically important than M3 receptors on smooth muscle. M4 receptors are present on neutrophils and eosinophils, whereas M5 receptors are present on neutrophils and lymphocytes. The importance of these neurogenic mechanisms compared with inflammatory and immunologic mechanisms in the pathogenesis of asthma has long been debated and often underappreciated. Preganglionic nerves release the cholinergic neurotransmitter acetylcholine and supply clusters of postganglionic cell bodies located in parallel chains along smooth muscle of the trachea and bronchi. Cholinergic postganglionic fibers do not extend beyond the terminal bronchi,18 consistent with the absence of functional changes in respiratory bronchioles or alveoli with vagal stimulation. Muscarinic Receptor Effects on Airway Smooth Muscle Tone In humans and animals, some degree of resting bronchomotor tone occurs because of tonic vagal nerve release of acetylcholine adjacent to airway smooth muscle. Submucosal glands are innervated and express M1 and M3 receptors in approximately a 1:2 ratio. There is evidence that through activation of muscarinic receptors on inflammatory cells and production of acetylcholine from nonneuronal sources, various inflammatory processes are promoted, including lymphocyte proliferation and activation, cytokine release, cytotoxicity, and eosinophilic chemotactic activity. Considering the stimulatory effect of M1 and M3 receptors and the overall inhibitory effect of M2 receptors, the optimal pharmacologic profile for anticholinergic agents in obstructive lung disease is antagonism of M1 and M3 receptors with minimal affinity for M2 receptors. As a tertiary amine, atropine is systemically absorbed even when administered locally to the airways, and it lost favor because of its significant anticholinergic adverse effects, including decreased pulmonary mucociliary clearance, urinary retention, and increased intraocular pressure. They have relatively little absorption through respiratory mucosa, do not penetrate the bloodbrain barrier, and usually avoid the systemic adverse effects associated with atropine. When used at approved doses in pulmonary airways, ipratropium and tiotropium do not significantly alter mucociliary clearance or respiratory secretions. Ipratropium Bromide Ipratropium bromide is a nonselective antagonist of M1, M2, and M3 receptors.

The phase I metabolic biotransformation of drugs spasms lower right abdomen buy nimodipine 30 mg with mastercard, which consists of introducing or exposing a functional group on the parent compound muscle relaxant cz 10 30 mg nimodipine order, is generally enzymatic and primarily occurs in the liver muscle relaxant drug list 30 mg nimodipine buy with amex. As a result of low substrate specificity among P-450 isozymes spasms in upper abdomen buy 30 mg nimodipine fast delivery, more than one may catalyze a given biotransformation; however muscle relaxant buy cheap nimodipine 30 mg on line, many drugs are primarily metabolized by one subfamily. Clearance is the primary determinant for developing dosing regimens of systemic drugs for longterm administration. Clearance (Cl) is defined as the volume of blood or plasma that is completely cleared of drug over a unit of time. More clinically relevant is that the steady-state concentration (Cpss) of drug occurs when the dosing rate equals the rate of drug elimination, and the Cpss is determined by the clearance as follows: Cpss = Dosing rate Cl [87. Thus the amount of drug eliminated over a unit of time increases as the concentration increases, producing a constant percentage of drug lost per unit time (first-order elimination kinetics). In contrast, if saturation occurred, a constant amount of drug is eliminated per unit time (zero-order kinetics). For chronic dosing of drugs undergoing first-order elimination, it is easy to see that, with the clearance unchanging, any change in dosing rate will result in a proportional change in steady-state concentration. Theophylline, a drug with a narrow therapeutic index, occasionally exhibits nonlinear kinetics in the usual therapeutic range of serum concentrations, particularly in children. This refers to clearance calculated from oral dosing when absolute bioavailability is unknown, and it should not be confused with actual clearance. Drugs with a high first-pass effect will have higher oral clearance than actual clearance; however, the oral clearance would be the more appropriate value to use in determining oral dosage regimens for the drug. Cf 1 Half-Life Drugs undergoing first-order elimination kinetics can be characterized by their half-life. The half-life is the time it takes to eliminate one-half of the drug from the body or to reduce the serum concentration by one-half. The elimination half-life of a drug depends on both the previously discussed physiologically defined pharmacokinetic variables, Vd and Cl, as follows: Cl (organ function) 0. The Cl determines how much of the blood is cleared of drug, and the Vd determines how much drug is presented to the clearing organ in that unit of blood. As can be seen, only changes in clearance affect steady-state serum concentrations (Eq. Changes in Vd affect the time to reach steady-state concentrations but not the final concentration, which is determined by the dose and clearance. For example, a highly lipophilic inhaled corticosteroid will have the same steady-state serum concentration as a more hydrophilic one with a lower Vd if they have the same clearance. First, it helps to determine a reasonable dosing interval for a chronically administered drug. Second, the half-life, in conjunction with the absorption rate, determines the fluctuation of serum concentrations over the dosing interval. The elimination half-life will generally determine the pharmacologic duration of action of a drug unless the effect at the receptor lasts significantly longer. After one half-life, 50% of the drug is left; after two half-lives, 25% remains; after five half-lives, only 3. Thus clinically the drug is essentially eliminated from the body in five half-lives. This is the same time that it takes to reach any new steady state after a dosage change. Thus the clinician can use the half-life to determine when to evaluate the effects of a new dosage or whether using a loading dose or holding doses may be more prudent to effect faster change. When using this information, the clinician can more logically decide how to begin dosing and how to monitor therapy. In drugs with extremely long half-lives, the use of loading doses may be appropriate. Also, the steady-state concentration depends only on the maintenance dose and clearance, whereas the loading dose is estimated from the Vd. Thus, after a loading dose, the serum drug concentration will increase or decrease over the five half-lives to achieve the final steady-state concentration. If plasma concentrations are much less than Km, elimination will follow first-order kinetics and appear linear. Steady state can be estimated by the following equation: Cpss = (Dosing rate)(K m) Vm - Dosing Rate [87. However, in recent years the study of pharmacokinetics in relation to pharmacodynamics has shown that pharmacodynamic variability plays an important role in interindividual and intraindividual response to drugs. Some of the factors that produce pharmacodynamic differences, such as tolerance and tachyphylaxis, have been well documented and mechanistically explained, whereas others, such as functional antagonism, the effect of inflammation on receptor activity, pharmacogenomics, and chronopharmacology, have been observed but less well investigated. Intact tissue or in vivo pharmacodynamics illustrates factors affecting response other than classic mass-action receptor theory. However, alteration of the concentration-response or doseresponse curves by pathophysiologic changes has drawn great interest in recent years. Functional antagonism is a phenomenon used to explain changes in the dose-response characteristics of bronchodilators. Potential bronchodilators are often screened in vitro with isolated smooth muscle preparations that are contracted with low concentrations of histamine or an acetylcholine derivative. Partial agonists are more easily antagonized than full agonists; therefore the expression of shifting the dose-response curve depends on the contractile agonist used, because partial-contractile agonists are less likely to induce the effect. Nonasthmatic healthy individuals have a circadian change in pulmonary function, and some asthmatic patients have an exaggerated decrease with a nadir at 4 to 5 am and a peak in the early afternoon. Patients with nocturnal asthma have increased bronchial hyperresponsiveness and increased leukotriene excretion at night. The dosing of montelukast once nightly was designed to produce maximal drug concentration in the late-night and early-morning hours. Tolerance Tolerance or desensitization of agonist receptors with continued stimulation is a well-described phenomenon in clinical pharmacology. Desensitization of 2-adrenergic receptors has been the most extensively studied and is reviewed in more detail in Chapter 93. Desensitization of 2-receptors may occur by at least three mechanisms: phosphorylation, sequestration, and downregulation. Sequestration also follows short-term exposure but requires drug occupancy and reverses immediately after dissociation of the drug from receptor. However, if the agonist remains coupled for a sufficient period of time (hours), downregulation occurs in which receptor numbers diminish. Interestingly, the susceptibility of 2-receptors to downregulation appears to be genetically determined. In addition to the receptor-based mechanisms, a postreceptor mechanism of desensitization is believed to be likely. Although glucocorticoid resistance occurs, it is thought to be a result of inflammation and not agonist-induced tolerance. Gene polymorphisms have been associated with altered responses to 2-agonists, glucocorticosteroids, and leukotriene modifiers. Drug interaction effects can be related to other interfering drugs or even alterations in disease state that affect the clinical activity or usefulness of a drug. Drug interactions may produce beneficial results, as well as potentially adverse effects. Numerous drugs with the potential for adverse consequences are frequently administered together without problems. Indeed, it is difficult to determine the risk of adverse consequences of drug interactions because the denominator (total number of patients receiving the combination) is largely unknown due to the inefficiency of voluntary reporting mechanisms. Adverse drug reactions are increasingly recognized as a significant medical problem, with a median hospitalization prevalence rate of approximately 12% world-wide,52 and the clinician needs to be cognizant of the possibility of enhancing adverse drug reactions through drug interactions. Drugs associated with severe toxicities and a narrow therapeutic index are more likely to be associated with significant drug interactions. In addition, drug interactions are more likely to be detected with drugs whose serum concentrations are routinely monitored in clinical practice. Adverse consequences from drug interactions can also occur as a result of severe exacerbation of disease resulting from the lost therapeutic effect from a drug. Many drug interactions go undetected in initial clinical trials unless there is reason to suspect a possible interaction. For example, how many patients received the combination of erythromycin and theophylline with or without adverse consequences before the publication of the interactions As more immunomodulators are developed, drug­immune system interactions are expected to increase. Although the actual risk of a serious outcome may be low, the seriousness of the adverse effects warrants preventive measures to reduce the risk. Pharmacokinetic Interactions the vast majority of drug interactions fall into the pharmacokinetic category. Drugs that are most likely to undergo significant interactions are those drugs that are primarily eliminated by hepatic metabolism. Understanding which of the P-450 isozymes is involved in the metabolism of a drug enhances the capability to predict interactions. An understanding of the time course of pharmacokinetic interactions allows the clinician to monitor patients appropriately to avoid potential adverse consequences. Enzyme induction requires synthesis of new enzymes; thus a 3- to 4-day delay occurs for new protein synthesis before any change is seen. The offset is also delayed by the time it takes to eliminate the inducer and then eliminate the excess enzymes. The maximum effect depends on the dose of the inducing medication and requires a 100% increase in clearance to produce a 50% reduction in steady-state serum concentration of the coadministered medication. Although understanding the time course allows the clinician to monitor patients given interacting drugs, it is more prudent to avoid potentially serious interactions altogether. The factors contributing to altered response are a reminder that drug therapy often requires individualization. With newer immunomodulator products available and expected to be developed, greater pharmacovigilance for drugimmune system adverse effects that will require long-term observation is required. Update on current concepts of the molecular basis of 2-adrenergic receptor signaling. Histamine H1 receptor activation of nuclear factor-B: roles for G- and G(q/11)-subunits in constitutive and agonist-mediated signaling. Interactions between corticosteroids and beta-adrenergic agonists in asthma disease induction, progression, and exacerbation. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Enantiomers of bronchodilating beta2-adrenoceptor agonists: is there a cause for concern Significant variability in response to inhaled corticosteroids for persistent asthma. Role of phosphoinositide metabolism in human bronchial smooth muscle contraction and in functional antagonism by beta-adrenoceptor agonists. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients; final rule docket no 97N-0165. Predicting drug disposition, absorption/ elimination/transporter interplay and the role of food on drug absorption. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Applied pharmacokinetics and pharmacodynamics principles of therapeutic drug monitoring. A systematic review of hospitalization resulting from medicine-related problems in adult patients. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. An evaluation of the quinolone-theophylline interaction using the Food and Drug Administration spontaneous reporting system. Incidence and cost of hospital admissions secondary to drug interactions involving theophylline. Understanding how long-acting beta2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update. Comparison of human bronchial muscle responses to histamine in vivo with histamine and isoproterenol agonists in vitro. Influence of tracheal contraction on relaxant effects in vitro of theophylline and isoprenaline. In vivo functional antagonism between isoproterenol and bronchoconstrictants in the dog. Effects of theophylline on inhaled methacholine and histamine in asthmatic children. Enzymatic activity, hepatic function, and renal function are the principal physiologic determinants of drug clearance. Clearance is most easily determined by administering a continuous infusion of a drug and measuring concentrations after steadystate has been reached. Drugs with a high first-pass effect have a larger oral clearance than actual clearance. For most drugs, the clearance remains constant over the range of concentrations experienced clinically. The assessment of the actual rate of adverse effects from a drug is often difficult to assess because: a. It is often difficult to know the number of persons exposed to the drug to determine incidence and prevalence of adverse effects. Both pharmacodynamics and pharmacokinetic interactions can occur, including interactions with disease state, which may make it difficult to determine the causative drug. Is directly proportional to clearance, so if clearance increases, half-life also increases.

Cheap nimodipine 30 mg buy on-line. 20151117 Neuromuscular Blocking Agents Basic Pharmacology.

Tailored education may reduce health literacy disparities in asthma self-management infantile spasms youtube order generic nimodipine online. Antecedents of adherence to medical recommendations: results from the Medical Outcomes Study muscle relaxant education order 30 mg nimodipine mastercard. Cultural competence policies and other predictors of asthma care quality for Medicaid-insured children spasms around the heart nimodipine 30 mg order with amex. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma spasms back muscles cheap 30 mg nimodipine with mastercard. Noncommunicable Diseases and Mental Health Adherence to Long Term Therapies Project spasms 1983 wikipedia nimodipine 30 mg sale. A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. Influences of earlier adherence and symptoms on current symptoms: a marginal structural models analysis. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Adherence and persistence with fluticasone propionate/salmeterol combination therapy. Drop-out rate among patients treated with omalizumab for severe asthma: literature review and real-life experience. Adherence monitoring and e-health: how clinicians and researchers can use technology to promote inhaler adherence for asthma. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Maternal depressive symptoms and adherence to therapy in inner-city children with asthma. Perception of airway obstruction in asthma: sequential daily analyses of symptoms, peak expiratory flow rate, and mood. Common measures of asthma severity lack association for describing its clinical course. A pharmaco-epidemiologic survey on perennial allergic rhinitis in every day medical practice in France. Patient preferences for sensory attributes of intranasal corticosteroids and willingness to adhere to prescribed therapy for allergic rhinitis: a conjoint analysis. Medical costs and adherence in patients receiving aqueous versus pressurized aerosol formulations of intranasal corticosteroids. Psychological factors associated with medication nonadherence in asthmatic children. The development of a motivational interviewing intervention to promote medication adherence among inner-city, African-American adolescents with asthma. A pilot study to enhance preventive asthma care among urban adolescents with asthma. Efficacy of brief motivational interviewing to improve adherence to inhaled corticosteroids among adult asthmatics: results from a randomized controlled pilot feasibility trial. Adherence feedback to improve asthma outcomes among inner-city children: a randomized trial. Providing feedback on adherence increases use of preventive medication by asthmatic children. Effectiveness of Population Health Management Using the Propeller Health Asthma Platform: a randomized clinical trial. Long-term effects of asthma education for physicians on patient satisfaction and use of health services. A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study. Shared treatment decision making improves adherence and outcomes in poorly controlled asthma. Shared decision making and motivational interviewing: achieving patient-centered care across the spectrum of health care problems. A patient advocate to facilitate access and improve communication, care, and outcomes in adults with moderate or severe asthma: rationale, design, and methods of a randomized controlled trial. Treating asthma with a self-management model of illness behaviour in an Australian community pharmacy setting. Test of an interactive voice response intervention to improve adherence to controller medications in adults with asthma. Which is the most accurate way to measure inhaled corticosteroid adherence in a clinical trial The availability of humanized monoclonal antibodies against IgE has provided a therapeutic option and tool to more closely explore the role of IgE in allergic diseases and the effects of inhibiting IgE itself. The binding of omalizumab to IgE results in the formation of soluble immune complexes that are subsequently cleared by the reticuloendothelial system. In other words, omalizumab can bind only to soluble IgE, and therefore cannot precipitate degranulation of effector cells. Elevation of total serum IgE is typically found in many atopic patients, and in predisposed individuals, allergen-specific IgE is produced. Cross-linking of two adjacent IgE molecules on the surface of allergic effector cells initiates intracellular signaling pathways that result in the release of preformed and rapidly synthesized mediators. Inhibition of the consequences of mast cell and basophil degranulation has been an important therapeutic goal for many years. Chronic therapy of allergic diseases has largely been limited to blocking the IgE and IgE Receptors IgE is present in the serum in far lesser amounts than IgG, IgM, or IgA with a half-life in the serum of only 2 days. Subjects underwent sputum induction and bronchoscopy with bronchial biopsy before and after treatment. Treatment with omalizumab resulted in a significant decrease in the mean percentage of sputum eosinophils from 6. Highly cytokinergic IgEs induced production of cytokines and rendered mast cells resistant to apoptosis in an autocrine fashion. Omalizumab treatment has been shown to induce human eosinophil apoptosis in patients with allergic asthma. After 12 weeks of therapy with omalizumab markers of eosinophil apoptosis (Annexin V) were significantly increased. A 99% reduction in free serum IgE levels has been noted within 2 hours of omalizumab administration. Furthermore, within 3 months of therapy, human basophil responsiveness (histamine releasability) was reduced by 90%. This has resulted in the unreliability to use skin test responses as a surrogate biomarker to regulate and explore dosing effects of this agent. A Phase-2 study examined asthma symptom scores in 317 moderate to severe allergic asthmatics on inhaled and/or oral corticosteroids. Subjects in the omalizumab treatment groups had fewer asthma exacerbations and were able to reduce or discontinue corticosteroids to a greater extent than subjects treated with placebo. Three Phase-3 trials were conducted on a total of 1405 patients with moderate to severe allergic asthma. During the initial 16 weeks, omalizumab was added on to inhaled corticosteroids at a stable dose. The primary endpoint in all three studies was a reduction in asthma exacerbations. Omalizumab led to a significant reduction in asthma exacerbations compared with placebo in all three studies. Furthermore, omalizumab demonstrated a corticosteroid-sparing effect in all three studies. There were a twofold greater number of subjects in the omalizumab group who successfully discontinued corticosteroids compared with placebo-treated subjects. In addition, fewer asthma symptoms, less rescue medication usage, and improved quality-of-life scores were noted in the omalizumab-treated patients. To examine baseline characteristics predictive of a response to omalizumab, data from 1070 adolescents and adults from two of these Phase-3 trials were pooled. The greatest benefits were noted in patients who had two or more of these characteristics. Omalizumab prevented exacerbations in about 17 additional patients for every 100 treated. Fifty percent of potential exacerbations were prevented by treatment with omalizumab, and 5. At 32 weeks a significant reduction in the dose of inhaled corticosteroids in the omalizumab group compared with placebo (mean 57. Improved symptoms, less rescue medication usage, and improved quality of life were also observed in the omalizumab group compared with placebo. In practice, omalizumab is typically added to the therapeutic regimen in patients who remain poorly controlled despite maximal medical therapy. The addition of omalizumab to maximal conventional asthma therapy was evaluated in a 52-week trial in patients with moderate to severe allergic asthma who were symptomatic, despite treatment with high doses of inhaled corticosteroids plus long-acting 2-agonists, antileukotrienes, or oral steroids. A similar study evaluated 419 patients with severe uncontrolled asthma despite high-dose inhaled corticosteroids and long-acting bronchodilators. In addition, quality-of-life scores, pulmonary functions, and asthma symptom scores improved with omalizumab add-on therapy. Another study evaluated the pooled data from five double-blind trials and two open-label studies for an analysis of the effect of add-on therapy with omalizumab on asthma exacerbations in severe asthmatics. Omalizumab decreased the rate of asthma exacerbations by 38% and also decreased the rate of emergency visits by 47%. Omalizumab also significantly improved symptom scores, quality of life, and rescue medication use. These effects were independent of age, duration of treatment, or severity of asthma. In addition, there was no difference in adverse events or serious adverse events between omalizumab and placebo treatment. Data from two Phase-3 clinical trials of omalizumab in patients with allergic asthma were examined for predictors of response. Patients with clinical markers of greater asthma severity or high baseline blood eosinophil count had a more pronounced reduction of asthma exacerbations requiring systemic steroid therapy when treated with omalizumab than patients with asthma who did not have these markers. The cost of treatment can approach $36,000 in patients who require 375 mg every 2 weeks, the top of the dosing table. However, despite its high cost, it may still be cost-effective when its use is limited to those patients with more severe disease. This includes patients with frequent exacerbations, those requiring emergency care, and those patients requiring hospitalization. It is this relatively small group of patients who account for the bulk of health care expenditures associated with asthma care. Together, these studies indicate that omalizumab is effective as an add-on therapy in severe adult asthmatics who are poorly controlled despite maximal medical therapy. In 478 children 6 to 17 years of age treated with omalizumab, fall exacerbation rates were lower (11. Subsequent evaluation noted that omalizumab decreased duration, peak shedding, and frequency of rhinovirus illnesses in children with allergic asthma. A 24-week, multicenter, parallel group, double-blind, randomized, placebo-controlled trial on patients with symptomatic asthma despite inhaled corticosteroids evaluated exacerbation rates with 6 months of anti-IgE therapy. In patients with the low baseline eosinophil counts, no Allergic Rhinitis the effect of omalizumab was evaluated in 536 patients with ragweedsensitive allergic rhinitis. Omalizumab or placebo was administered just prior to the onset of the ragweed season and every 3 to 4 weeks throughout the pollen season. In addition, a significant correlation was observed between reduction in serum IgE and improvements in nasal symptoms and rescue antihistamine use. Another large seasonal allergic rhinitis study examined the therapeutic benefits of omalizumab in 251 birch-pollen sensitive rhinitics. The omalizumab-treated group showed significant improvements over placebo in average daily symptom scores, usage of rescue antihistamines, and quality-of-life measures. In patients with ragweed-induced allergic rhinitis, omalizumab has been safely readministered in a subsequent year after discontinuation following the previous ragweed season. A group of 289 patients with moderateto-severe disease were evaluated in a 16-week trial. Fewer asthma exacerbations were observed in the omalizumab-treated patients than placebotreated patients (20. Furthermore, more patients in the omalizumab group demonstrated a clinically significant improvement in both asthma and rhinitis quality of life indices (57. This suggests omalizumab is effective in the treatment of upper and lower airway symptoms in the same patients. Allergen immunotherapy has been used for 100 years for the management of allergic disorders and is the only antigen-specific immunomodulatory treatment routinely available to clinicians. Omalizumab does not completely ameliorate symptoms of allergic respiratory symptoms, and upon discontinuation, serum IgE levels return to pretreatment levels. The addition of omalizumab to standard maintenance dose immunotherapy was evaluated in 221 children and adolescents with sensitization to birch and grass allergen. Similar results were seen in grass season with irrelevant (birch) immunotherapy and omalizumab decreasing symptoms by 45%, whereas patients on grass immunotherapy and omalizumab had a reduction in symptom scores by 71% compared with irrelevant immunotherapy and placebo. When these findings were further analyzed for the grass pollen-allergic children, it was noted that omalizumab plus immunotherapy treated groups had significantly diminished rescue medication usage and number of symptomatic days when compared to either omalizumab or immunotherapy alone. The primary objective of a second study was to determine whether omalizumab, given 9 weeks prior to rush immunotherapy, followed by 12 weeks of dual omalizumab and immunotherapy, is more effective than rush immunotherapy followed by immunotherapy alone in ragweed allergic patients. Patients receiving omalizumab plus immunotherapy had fewer adverse events than those receiving immunotherapy alone. Post hoc analysis of groups receiving immunotherapy demonstrated that the addition of omalizumab resulted in a fivefold decrease in risk of anaphylaxis caused by rush immunotherapy (odds ratio, 0. On an intent-to-treat basis, patients receiving both omalizumab and immunotherapy showed a significant improvement in severity scores during the ragweed season compared with those receiving immunotherapy alone (0. In addition, omalizumab patients were more likely to achieve maintenance dosing, 87% compared with placebo at 72%.

Inhaled -agonists administered prior to allergen inhibit the early asthmatic response spasms right side of back order genuine nimodipine on-line, probably mainly via the functional antagonist effect111; however muscle relaxant id order nimodipine 30 mg fast delivery, there is also an effect on mast cell mediator release muscle relaxant kidney stones order 30 mg nimodipine free shipping. The clinical correlate of this would be subjects who use 2-agonists alone prophylactically to allow more prolonged exposure to a naturally occurring allergen muscle spasms 37 weeks pregnant buy nimodipine toronto, an approach that can predictably cause exacerbation of asthma later on muscle relaxant 25mg nimodipine 30 mg purchase. Long-acting inhaled 2-agonists have a prolonged duration of action that will mask the late response and increased airway responsiveness. Theophylline partially inhibits the early and late responses116,117 and is not very effective in blocking increased airway responsiveness. Agents can be broadly differentiated into high molecular weight IgEstimulating protein-containing allergens and low molecular sensitizers, the immune pathogenesis for the latter being uncertain. This requires a prolonged challenge procedure in which the exposure is increased by perhaps a factor of four at 24-hour intervals, monitoring the patient daily for 7 hours, usually rechecking their airway responsiveness (methacholine) each afternoon. It also means that a challenge with a single agent can take as long as 5 complete working days. The other important caveat is the requirement for a means of generating a reproducible dose/concentration of the suspected sensitizer. This may require an isocyanate monitor or some means of monitoring the size and volume of dispersed particles137 and a dedicated occupational exposure chamber,138 preferably in a hospital setting. Occupational challenges should be limited to centers and physicians with expertise in this area. The remaining aspects of occupational challenges are similar to those of allergen challenges, including monitoring of airway function for 7 hours after each exposure, performance of methacholine tests after each exposure, usually in the afternoon after 7 or 8 hours, and ideally the evaluation of airway inflammation as well. With rare exceptions, allergen challenges must be considered exclusively a research tool. Allergen challenges in particular have provided remarkable insight into the pathogenesis of IgE-mediated asthma. They are particularly useful in the investigation of potentially new asthma treatments. Inhalation challenge with occupational agents, particularly low molecular weight sensitizers, is the other selective challenge reviewed. These challenges are even more complex and time-consuming than the already time-consuming allergen challenge. Inhalation challenges remain the only way to confirm sensitization to a low molecular weight agent encountered in the occupational setting. Because of the complexities involved in both performance and interpretation, it is recommended that occupational challenges be restricted to specialized centers with particular expertise in this area. Summary Bronchial inhalation challenges have provided valuable insight into the pathogenesis and treatment of asthma. The nasal mucosa is the most common site of allergic inflammation, and its accessibility makes it ideal for the study of allergic and inflammatory mechanisms. Nasal allergen provocations are safe with very low risk of inducing systemic allergic reactions or bronchospasm. They have been invaluable in studying mechanisms of allergic inflammation and in the assessment of responses to new and established antiallergic treatments. Use of nasal provocation may have greater sensitivity to detect treatment effects than assessment of seasonal symptoms alone. Provocation testing may increasingly have a role in clinical practice, such as in diagnosis of occupational rhinitis, identification of local allergic rhinitis and selection of patients for allergen immunotherapy. Direct nonselective bronchoprovocation, generally using methacholine, is the most widely performed inhalation challenge. The test has a high diagnostic sensitivity for asthma provided symptoms are clinically current. Methacholine tests function best to exclude asthma with reasonable certainty when the results are negative. A positive test in the presence of typical symptoms provides documentation of airway dysfunction and a physiologic rationale for trials of asthma treatment. Important caveats to the interpretation of methacholine challenge include the requirement for symptoms to be clinically current and the requirement for normal baseline spirometry. Nasal Allergen Challenge Nasal allergen provocations have provided insights into the pathophysiology of allergic rhinitis. Following challenge, the immediate symptoms of itching, sneezing, rhinorrhea, and nasal congestion correspond to increases in glandular secretion,140 plasma extravasation,141 and mast cell and basophil degranulation. More recently, it has been used to redefine a cohort of patients, previously diagnosed with nonallergic rhinitis, with local allergic rhinitis. These challenges have increased diagnostic specificity and reduced diagnostic sensitivity and are consequently more useful to confirm a diagnosis of asthma. The newly developed mannitol inhalation challenge shows promise and may well become the indirect challenge of choice. Nasal examination is needed to assess potential contraindications and confounding factors such as nasal polyps, septal deviation, sinusitis, or concurrent coryzal illness. Although nasal allergen provocation is extremely safe, caution should be applied in patients with poorly controlled asthma. Other possible contraindications include use of -blockers, active nasal bleeding, and a history of anaphylaxis or significant angioedema potentially attributable to the provoking allergen. If needed, medications with antiallergic effects should be discontinued for an appropriate period before provocation. The timing of the provocation procedure should take into account seasonal triggers and priming due to other allergens. Tests should be undertaken at the same time of day to control for diurnal variation. Many researchers perform a provocation at screening, with a minimum level of reactivity required for study inclusion. The latter produces a dose-response curve, which may provide a more sensitive tool to detect changes in reactivity following a treatment intervention. Repeat tests have been performed over several days to simulate real-life seasonal exposure and investigate nasal priming. Cotton wool has been replaced by synthetic discs or strips147 and open cell polyurethane sponges161 for direct collection of nasal lining fluid. Fluid may then be extracted from these materials by centrifuging across a microfilter162 with or without use of an elution buffer. Secretions are tested by sensitive immunoassays, with the ability to measure multiple mediators down to pg/mL levels in volumes of 100 µL or less. A study comparing four different collection methods, lavage, nasal fluid blowing, filter paper, and polyurethane foam, showed no evidence of mucosal injury-as indicated by lactate dehydrogenase release-for any of the techniques. Levels of mediators recorded were approximately 10 times higher with the foam than with lavage, with far fewer samples below minimum detection levels. Provocations are generally carried out with a single allergen, although challenge to multiple allergens simultaneously has been described as a means of screening for local allergic rhinitis in appropriate patients. Nasal spray dose-applicator devices are the most straightforward to use and administer a fixed volume per actuation, but there is a risk of failed or incomplete sprays. Filter discs impregnated with allergen may be applied to the nasal mucosa, typically onto the inferior turbinate under direct guidance, and may also be used to collect nasal secretions. Nasal lavage provides fluid and cells for analysis and is unlikely to have a significant irritant effect on the nasal mucosa. However, the dilution factor for measured mediators and cells is difficult to determine, meaning results are semiquantitative Environmental Exposure Chambers. High dose nasal allergen provocation is clearly different from real-life daily, low-level, chronic particulate exposure. Environmental exposure chambers provide controlled temperature, humidity, and particulate allergen exposure at levels comparable to natural exposure. Chamber studies have been recently used to assess efficacy of a range of immunotherapy products. Symptoms are typically divided into four categories: itch, running, sneezing, and blockage, with a score from 0 (no symptoms) to 3 (severe symptoms) for each category. There are variations within the literature, with some scoring systems adding a separate category for eye symptoms. An alternative, or complementary approach, has been the use of visual analogue scales. Disadvantages Loss of fluid to nasopharynx and sinuses; unknown dilution; dilution below minimal levels of detection. Low volumes of neat fluid; eluting in solution may dilute to below minimal detection levels; skill required in application. Lower patient tolerability; risk of physical/irritative effect; skill in application; potential for protein sticking to matrix. Reference 143,144 147,206 150,161­163 Methods of Fluid Collection Methods of Cell/Tissue Collection Technique Nasal scraping Nasal brushing Nasal biopsy Advantage Simple to perform Simple; good correlation with mucosal biopsy Full thickness of mucosa; cell-mediator colocalization; architecture maintained. Technical expertise required; time-consuming; slight risk of bleeding, pain, infection. It is used to calculate airway resistance or conductance and may be performed by anterior or posterior techniques. Passive anterior rhinomanometry involves passing a fixed flow into one nostril and recording the pressure induced as a result of resistance to flow. Acoustic rhinometry is used to measure the cross-sectional area of the airway as a function of distance into the airway. The test is most accurate for the anterior aspect (2 to 6 cm) of the nasal passage and is performed in each nostril independently. Despite these scores being subjective, they provide highly reproducible results, potentially more than the more complex physiological tests of nasal airway function outlined below. Objective measures of the nasal airways are not standardized to the same extent as bronchial peak flows or spirometry. Values are dependent on lung capacity in addition to nasal patency, making comparison between individuals difficult. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. Although the early phase is straightforward to record clinically and align with increased levels of tryptase or histamine, the clinical late phase is subtler, or even absent, despite marked increases in Th2 cytokines and eosinophilic inflammation. Assessment of antiallergy treatments has demonstrated parallel decreases in clinical symptoms and biomarkers, including for topical steroids,177 antihistamines,180 and allergen immunotherapy. For whole cell counts, cell isolation and resuspension is generally followed by automated estimation of total cell numbers, followed by cell staining and manual/automated counting of the desired cell type. Although allergen challenge affects levels of eosinophils, neutrophils, basophils, epithelial cells, lymphocytes, and recently described type 2 innate lymphoid cells,183 researchers have generally targeted eosinophils as the most specific marker of an allergic response. Performing cell counts is labor-intensive and to some extent has been replaced by immunoassays of biomarkers of eosinophilic inflammation, as described previously. Because it is minimally invasive, multiple samples can be taken before and after challenge. This method has proved useful to look at changes in cellular profiles using flow cytometry183 and transcriptomics after nasal allergen challenge. Biopsies may be taken from the inferior turbinate under local anesthetic and topical vasoconstrictor, using specially designed forceps. Discomfort responsive to paracetamol and bleeding controllable by finger pressure are not uncommon side effects but are usually mild. This technique has been used to definitively confirm basophil and eosinophil influx into the nasal mucosa after allergen challenge,187,188 to provide further evidence of mast cell degranulation,187 to study the role of T cells, and to investigate the effects of intranasal corticosteroids on nasal allergen provocation. Low concentrations mean levels may be undetectable by nasal lavage, but collection by filter paper or sponges is more sensitive. Low levels, often below assay detection limits; but some studies have shown increase after allergen challenge. Elevated from 4 hours postallergen challenge; inhibited by intranasal corticosteroids. Lysozyme secretion unaffected by topical intranasal corticosteroids; but suppressed by topical olopatadine. Unilateral histamine provocation by filter discs induced contralateral effects (predominantly increased secretions) that could be blocked by contralateral application of atropine. Both ipsilateral and contralateral effects could be blocked by ipsilateral application of lidocaine. Histamine levels have also been shown to increase bilaterally following unilateral allergen provocation, suggesting the possibility of neuronally induced mast cell or basophil degranulation. Unilateral nasal allergen provocation can induce not only contralateral nasal symptoms, but bilateral eye symptoms. Allergen-specific IgE may be detected in their nasal fluid, suggesting a local allergic response rather than a simple irritant effect. This has been demonstrated by nasal allergen provocations-threshold doses required to provoke symptoms decrease from preseason, through midseason, to end of season. Although it has generally been considered that such background exposures are likely to heighten responses to unrelated allergens, one study found that grass pollen­monosensitized individuals had greater symptom scores and falls in nasal inspiratory peak flow following grass provocation than individuals sensitized to both grass and dust mite. Repeat challenges (distinct from dose-titration challenges) have been used to mimic the priming effect of persistent seasonal allergen exposure. In these models, the most striking effects appear to be on inflammatory biomarkers or cells, rather than patient-reported symptoms or tests of airway function. Most studies have used a 24-hour time frame between challenges, with variable numbers of repeat challenges. Histamine provocation recreates all the early-phase symptoms of allergen provocation, but does not induce a significant late-phase response. Histamine tests show increased responsiveness during seasonal allergen exposure or following nasal allergen challenge and may be inhibited by pretreatment with intranasal corticosteroids.

References

• Heuser M, Zapf A, Morgan M, et al. Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Ann Hematol 2011;90(3):273-281.
• US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics. 2010.
• Cserni T, Magyar A, Tamas Nemeth T, Paran TS, Csizy I, Jozsa T. Atresia of the ileocecal junction with agenesis of the ileocecal valve and vermiform appendix: report of a case. Surg Today 2006;36:1126.
• Roberts WC, Honig HS. The spectrum of cardiovascular disease in the Marfan syndrome: a clinico-morphologic study of 18 necropsy patients and comparison to 151 previously reported necropsy patients. Am Heart J. 1982;104:115-135.
• Theodorou C, Floratos D, Hatzinicolaou P, et al: Neurogenic bladder dysfunction due to Behcetis disease, Int J Urol 6(8):423n425, 1999.
• Westesson KE, Goldman HB: Prolapse of a single-system ureterocele causing urinary retention in an adult woman, Int Urogynecol J 24(10):1761n1763, 2013.